Kobori H, Ozawa Y, Suzaki Y, Prieto-Carrasquero MC, Nishiyama A, Shoji T, et al
581,582 It has undergone several clinical trials for various conditions, including Menieres disease (Phase III, NCT04677972), bipolar disorder, complete middle cerebral artery occlusion, delayed neurological deficits following aneurysmal subarachnoid hemorrhage, and acute ischemic stroke
This medicine contains Fluconazole, which belongs to a group of medicines called antifungals
For GLP-1 and metabolic peptide research including studies on compounds like retatrutide, tirzepatide, or semaglutide analogues the PSPen enables the precise daily dosing windows required by metabolic pharmacokinetic protocols
% Of patients waited 5 years or more for diagnosis % Of patients were initially misdiagnosed % Of patients are unhappy with their treatment Upcoming Events Become a Member of the Pernicious Anaemia Society With your help we can continue to do our valuable work, supporting those that need it and campaigning to secure future improvements in detection and treatment of this illness